Sign In
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- US Share Prices
- Stock Tips
- Share Chat
- FX
- News & RNS
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Faron Pharmaceuticals Share News (FARN)
FARN Share
Price
FARN Share
News
FARN Share
Chat2
FARN Share
Trades7
FARN
Live RNS
FARN Share
Charts
FARN Level 2
Console
FARN Live
Share Price
FARN Broker
Ratings
FARN Directors
Deals
FARN Financial
Diary
FARN
Fundamentals
FARN Short
Positions
FARN
Media
FARN Company
Research
FARN Company
Timeline
Share Price Information for Faron Pharmaceuticals (FARN)
Last checked at -
Last checked at 
Intraday Faron Pharmaceuticals Share Chart
Faron Pharmaceuticals Notes Study Supporting Clevegen Programme
LONDON (Alliance News) - Faron Pharmaceuticals Oy on Monday said an article published in the Journal of Immunology has outlined the functional role of the company's Clever-1 treatment, part of its Clevegen cancer immunotherapy antibody programme.
Faron, which floated in London earlier this month, said the data published in the study supported Clever-1 as an immuosuppresive molecule and supports the use of Clevegen as an immunotherapy product.
"We are working hard to advance our Clevegen programme, as announced recently, towards clinical use as a new onco-immunological alternative," said Faron Chief Executive Markku Jalkanen.
Shares in Faron were trading flat at 275.00 pence on Monday.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Latest FARN News
- Faron launches second phase of leukaemia treatment trial
9 Jan 2024 - Faron says first patient dosed in phase two Bexmab trial for cancer
9 Jan 2024 - Faron unveils promising antibody study results
11 Dec 2023 - Faron Pharmaceuticals hails positive results of cancer drug trial
11 Dec 2023 - IN BRIEF: Faron Pharma celebrates publication of bexmarilimab results
7 Dec 2023 - Faron publishes cancer immunotherapy study findings
7 Dec 2023 - IN BRIEF: Faron Pharmaceuticals starts Phase 2 of Bexmab trial
6 Nov 2023 - Faron reveals details of next stage of bexmarilimab study
6 Nov 2023
Related News
IN BRIEF: Faron Pharmaceuticals fined EUR30,000 by Nasdaq Helsinki
Faron Pharmaceuticals Ltd - Turku, Finland-based cancer drug developer - Says the Disciplinary Committee of Nasdaq Helsinki Ltd has imposed an EUR30,0...
WINNERS & LOSERS: James Cropper sees earnings up; Block sells stake
(Alliance News) - The following are the leading risers and fallers among London Main Market small-cap and AIM stocks on Tuesday.
Faron Pharmaceuticals News
Faron launches second phase of leukaemia treatment trial
(Sharecast News) - Faron Pharmaceuticals has initiated phase two of the BEXMAB trial, it announced on Tuesday, marking a significant milestone in its ...
Faron says first patient dosed in phase two Bexmab trial for cancer
(Alliance News) - Faron Pharmaceuticals Ltd on Tuesday announced that the first patient has been dosed in phase 2 of its Bexmab trial.
Faron unveils promising antibody study results
(Sharecast News) - Faron Pharmaceuticals unveiled promising phase one data from its BEXMAB study in myeloid malignancies during the 65th American Soci...
Faron Pharmaceuticals hails positive results of cancer drug trial
(Alliance News) - Faron Pharmaceuticals Ltd on Monday said results from a probe of a cancer drug were promising.
IN BRIEF: Faron Pharma celebrates publication of bexmarilimab results
Faron Pharmaceuticals Ltd - Finland-based clinical-stage biopharmaceutical company - Says that results from its Phase 1/2 MATINS trial of bexmarilima...
Faron publishes cancer immunotherapy study findings
(Sharecast News) - Faron Pharmaceuticals announced the publication of the comprehensive findings from the groundbreaking phase one and two 'MATINS' tr...
IN BRIEF: Faron Pharmaceuticals starts Phase 2 of Bexmab trial
Faron Pharmaceuticals Ltd - Finland-based clinical-stage biopharmaceutical company - Initiates Phase 2 of Bexmab study investigating humanised antibod...
Faron reveals details of next stage of bexmarilimab study
(Sharecast News) - Faron Pharmaceuticals announced on Monday that, following guidance from the US Food and Drug Administration (FDA), the initial indi...
Follow the stocks
